Authors
Latest:
Dr. Corr on the Utilization of Molecular Profiling in Endometrial CancerBradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.
Latest:
Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple MyelomaThe treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.
Latest:
Dr. Grunwald on the Clinical Implications of Tisagenlecleucel in B-ALL TreatmentMichael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.
Latest:
Dr. Shereck Highlights a Day In the Life of an Attending PhysicianEvan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she highlights the average work day as an attending physician.
Latest:
Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung CancerJohn F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.
Latest:
IU Cancer Researchers Refining Colorectal Cancer Classification, Identifying New Targets for Treatment Using Cutting-Edge, Single-Cell TechnologyAnalyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.
Latest:
Advice for Community Oncologists Treating Patients With R/R MMDrs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.
Latest:
Dr. Danila on Examining Immunotherapy in Early-Stage Prostate CancerDaniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.
Latest:
From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI CancerDaniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.
Latest:
Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast CancerRuchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.
Latest:
Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast CancerIsmail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast CancerIrene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.
Latest:
MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALLDoug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).
Latest:
Dr. Vijayvergia on the Efficacy of Pembrolizumab in MSI-H Advanced Gastric CancerNamrata (Neena) Vijayvergia, MD, discusses the efficacy of pembrolizumab with or without chemotherapy in patients with microsatellite instability–high advanced gastric cancer.
Latest:
Making Pancreatic Cancer Treatments More EffectivePancreatic cancer diagnoses are increasing more rapidly than any other cancer type while remaining one of the most deadly cancers.
Latest:
Patient Experiences Can Affect a Practice’s Financial HealthThe patient experience is a critical factor in the success of any healthcare practice, and its importance is increasing with the rise of health care consumerism.
Latest:
Dr. Bravo-Cordero on the Role of the Extracellular Matrix in Breast Cancer DormancyJose Javier Bravo-Cordero, MD, discusses the role of extracellular matrix proteomics and disseminating tumor cells when regulating the tumor microenvironment to induce dormancy in breast cancer.
Latest:
Closing Remarks on the Treatment of Patients With Metastatic MelanomaExperts share closing remarks and provide advice for clinicians treating patients with metastatic melanoma.
Latest:
Dr. Sezer on the FDA Approval of Cemiplimab in Frontline Advanced NSCLC With High PD-L1 ExpressionAhmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.
Latest:
Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRCSalvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.
Latest:
Dr. Vaishampayan on the PROBE Trial in Advanced RCCUlka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.
Latest:
Dr. Palmbos on the Utilization of Nivolumab Following Cystectomy in Muscle-Invasive Bladder CancerPhillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.
Latest:
Second-Line Treatment of SCLCVamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
Latest:
Metastatic Urothelial Carcinoma: Unmet Needs and Future DirectionsExpert reflection on the current unmet needs in metastatic urothelial carcinoma and hope for future improvements in the treatment armamentarium.
Latest:
Dr. Milhem on the Utility of RP1 in Solid TumorsMohammed Milhem, MBBS, MBBS, discusses the utility of vusolimogeneoderparepvec in solid tumors.
Latest:
Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GISTJohn Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.
Latest:
Comprehensive Treatment Advances Care for Patients With Early-Stage Breast CancerAdvances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.
Latest:
Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBCPramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.
Latest:
Palliative Care Builds Bridges in Oncology PracticeToby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.
